Clinical trial
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic…
NCT00275457 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00275457 |
|---|---|
| Title | Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients |
| Official title | A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | pramipexole |
| Enrollment | 346 |
| Start date | Oct 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Jan 12, 2006 |
| Last update posted | Oct 31, 2013 |
| Countries | Austria, Germany, Netherlands, Norway, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: